Invokana Lawsuit Alleging Drug Caused Development of Diabetic Ketoacidosis

April 19, 2016 – – TheProductLawyers.com reports on a lawsuit filed against Johnson & Johnson, specifically its subdivision Janssen Pharmaceuticals, identified with case number 1:15-cv-00636 in the Southern District Of Alabama concerning diabetes drug, Invokana. In her lawsuit, the plaintiff alleges that while using Invokana, a new-generation diabetes drug, she developed diabetic ketoacidosis. Further examination of the court documents showed that the plaintiff also claims she began using Invokana, an SGLT2 inhibitor drug, in December of 2014. She also alleges it was not long after that when she developed diabetic ketoacidosis, a potentially life-threatening medical condition.

If it remains untreated, diabetic ketoacidosis can be very dangerous. Ketoacidosis develops when the body’s bloodstream contains an excess of toxic acid due or ketones. It can develop suddenly, sometimes in as little as 24 hours, and has caused some patients to become comatose or die.

Those who have used Invokana or other similar SGLT2 inhibitor drugs are being asked by the U.S. Food and Drug Administration (FDA) to be on the lookout for signs denoting the development of ketoacidosis. The Mayo Clinic has identified certain signs of diabetic ketoacidosis which can consist of excessive thirst, frequent urination, nausea and vomiting, abdominal pain, shortness of breath, fruity-scented breath, and confusion.

Further reading of court documents have discovered that the plaintiff alleges she was never made aware of the possible risks of developing diabetic ketoacidosis while taking Invokana. She is claiming that Janssen Pharmaceuticals was grossly negligent and did not adequately warn medical professionals and patients of this potential side effect, as well as other possible side effects. The FDA, since the time of filing of the lawsuit, has also issued a public safety notice regarding the potential connection between taking Invokana and ketoacidosis, and has required the drug’s manufacturer to make changes to its warning labels to better explain this possible side effect as well as others.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009394